Metallomics

PAPER

Zinc is a transmembrane agonist that induces platelet activation in a tyrosine phosphorylation-dependent manner

Ben R. Watson, a Nathan A. White, b Kirk A. Taylor, b Joanna-Marie Howes, a Jean-Daniel M. Malcor, a Dominique Bihan, a Stewart O. Sage, c Richard W. Farndale a and Nicholas Pugh*ab

Following platelet adhesion and primary activation at sites of vascular injury, secondary platelet activation is induced by soluble platelet agonists, such as ADP, ATP, thrombin and thromboxane. Zinc ions are also released from platelets and damaged cells and have been shown to act as a platelet agonist. However, the mechanism of zinc-induced platelet activation is not well understood. Here we show that exogenous zinc gains access to the platelet cytosol and induces full platelet aggregation that is dependent on platelet protein tyrosine phosphorylation, PKC and integrin αIIIβ3 activity and is mediated by granule release and secondary signalling. ZnSO4 increased the binding affinity of GpVI, but not integrin αIIIβ3. Low concentrations of ZnSO4 potentiated platelet aggregation by collagen-related peptide (CRP-XL), thrombin and adrenaline. Chelation of intracellular zinc reduced platelet aggregation induced by a number of different agonists, inhibited zinc-induced tyrosine phosphorylation and inhibited platelet activation in whole blood under physiologically relevant flow conditions. Our data are consistent with a transmembrane signalling role for zinc in platelet activation during thrombus formation.

Introduction

Platelets are the principal cellular determinants of haemostasis and pathological thrombus formation leading to myocardial infarction and stroke. Following adhesion to sites of vascular damage, platelets undergo primary activation leading to shape change, upregulation of integrin αIIIβ3 activity and secretion of alpha and dense granules.1 Granule release introduces bioactive molecules into the immediate environment of a growing thrombus. Such molecules include adhesion proteins, coagulation factors and soluble platelet agonists, such as ADP, ATP, thromboxane-A2 and zinc.2–4

Plasma zinc concentration ranges from 10 to 20 μM, however, binding of zinc to plasma proteins lowers the free zinc concentration to 0.5 to 1 μM.5 Zinc is present in the cytosol and alpha granules of platelets at concentrations up to 60-fold higher than in the plasma.3,5,6 Upon platelet activation, zinc is released from platelets, contributing to a rise in the free zinc concentrations of the plasma and in the microenvironment of a growing thrombus.7,8

Endogenous zinc is also released or secreted from damaged cells and can act as a paracrine agonist of zinc-dependent signalling pathways in epithelial cells.9 Zinc has an acknowledged role in haemostasis. Low zinc diets are associated with platelet-related bleeding disorders in humans and rodents.10,11 Rats with acute and long term zinc deficiency have impaired platelet aggregation responses to ADP and thrombin,11,12 and rats fed with a high zinc diet show increased platelet responsiveness to collagen, ADP, thrombin and adrenaline.13 Additionally, zinc-deficient cancer patients exhibit cutaneous bleeding and platelet dysfunction that is reversed by zinc supplementation.14

Zinc has previously been shown to be a platelet agonist, with sub-millimolar concentrations of zinc being able to induce aggregation. Low concentrations of zinc potentiate ADP-induced platelet aggregation in an integrin αIIIβ3 dependent manner.15,16 However, the mechanism by which zinc causes platelet aggregation and its relative contribution to pathophysiological thrombus formation remains unstudied.

Here we confirm that zinc is a platelet agonist at millimolar concentrations, and is able to potentiate platelet activation at low micromolar concentrations. Furthermore, we investigated the mechanism of zinc-induced platelet activation using millimolar zinc. Zinc gains access to the platelet cytosol and induces
aggregation in a manner that is dependent on secondary activators, intracellular calcium release and tyrosine phosphorylation. The pattern of phosphorylated proteins is suggestive of a novel signalling pathway.

Our data are consistent with a role for zinc in platelet activation during haemostasis and pathogenic thrombus formation.

Results

Zinc is a platelet agonist

Previous studies have shown that 0.5 mM ZnCl₂ induces aggregation in both platelet rich plasma (PRP) and washed platelets, and that increasing the concentration further results in a reduced response.¹⁵,¹⁶ We confirmed this observation with the use of ZnSO₄ (Fig. 1). Complete aggregation of washed platelets was induced by 300 μM of ZnSO₄ (Fig. 1A and B). Aggregation was biphasic, indicating a reliance on secondary signalling. In agreement with previous reports, increasing zinc above 1 mM led to a reduced response. Of the other exogenously added cations tested (NiSO₄, LiSO₄, CuSO₄, CoSO₄, MgSO₄, MnCl₂), only CuSO₄ induced a partial response (Fig. 1B).

Zinc-induced platelet aggregation involves secondary mediators of platelet activation

In order to assess the influence of secondary signalling on zinc-induced aggregation, platelets were pre-treated with antagonists of secondary signalling pathways before being challenged with different concentrations of ZnSO₄.

Pre-treatment with the zβ₃ antagonist, GR144053 (2 μM) abolished platelet aggregation in response to 1 mM ZnSO₄ (Fig. 2A). Thus, zinc-induced activation results in zβ₃-dependent aggregation and is not dependent on cation-induced agglutination. Pre-treatment for 15 min with aspirin (1 mM), NF449 (P₂X₁ antagonist, 100 μM), 2-MeSAMP (P₂Y₁₂ antagonist, 100 μM) or PGE₁ (PG receptor antagonist, 2 μM) reduced zinc-induced aggregation (Fig. 2A). This indicates roles for secondary activation pathways (thromboxane A₂ and purinergic signalling) in zinc-induced aggregation, in addition to a role for CAMP in zinc-mediated signalling.

The profile of aggregation traces following aspirin, MeSAMP or NF449 treatment is suggestive of partial aggregation without secondary activation (not shown). DM-BAPTA-AM pre-treatment (10 μM) inhibited zinc-induced aggregation (Fig. 2A). This is consistent with a requirement for intracellular signalling which may include exogenous cation entry into the platelet cytosol or cation release from intracellular stores. Pre-treatment with the PKC antagonist GF109203X fully inhibited zinc-induced aggregation (Fig. 2A), indicating that zinc-dependent signalling pathways converge on PKC. We further investigated the influence of zinc on platelet activation with the membrane permeable zinc chelator, TPEN. TPEN pre-treatment inhibited zinc-induced aggregation to a similar degree to that caused by PGE₁, indicating that intracellular zinc is necessary for zinc-induced aggregation. The concentration of TPEN used here (50 μM) was effective when platelets were activated with 1 mM ZnSO₄, indicating that the inhibitory effect of TPEN was intracellular, and not caused by chelation of extracellular zinc ions prior to platelet activation.

To further investigate the involvement of secondary signalling, platelets were pre-treated for 15 min with a combination of aspirin (1 mM), NF449 (100 μM) and MeSAMP (100 μM) before being challenged with increasing concentrations of CRP-XL, thrombin or ZnSO₄. Whilst thrombin-induced aggregation was abolished (Fig. 2B and E), CRP-XL (Fig. 2C and F) and zinc-induced aggregation (Fig. 2D and G) were only partially inhibited. Thus, zinc-induced activation relies on secondary platelet signalling for a full aggregation response.

Zinc potentiates platelet reactivity to CRP-XL, thrombin and adrenaline

The data described in Fig. 1 and 2 suggest that zinc-induced platelet aggregation requires secondary agonists that are likely to be released in a PKC-dependent manner. However, the concentrations of zinc used here (0.1 to 1 mM) are higher than the local concentrations reported to occur during thrombus formation.⁷ Therefore, we investigated the potential of sub-activatory, pathophysiologically relevant zinc levels to potentiate platelet activation to different agonists. Sub-activatory concentrations
of 10 μM and 30 μM ZnSO₄ were used as these are only an order of magnitude greater than previously reported plasma free zinc levels.

Platelets potentiated with 30 μM ZnSO₄ showed an increased response to low concentrations of all agonists tested (Fig. 3). Pre-treatment with 30 μM ZnSO₄ followed by challenge with 0.01 μg mL⁻¹ CRP-XL resulted in 48.1 ± 10.6% aggregation, whereas non-potentiated platelets resulted in 10.1 ± 5.0% aggregation (Fig. 3A and D). Similarly, 0.03 U mL⁻¹ of thrombin failed to induce aggregation whilst potentiation with zinc restored aggregation to 60.6 ± 16.2% (Fig. 3B and E). Treatment of control platelets with adrenaline resulted in full aggregation following a lag period. Preincubation with zinc shortened this lag period at all adrenaline concentrations tested (Fig. 3C and F). For example, 1 μM adrenaline induced aggregation after a lag period of 586.6 ± 35.4 s. ZnSO₄ potentiation reduced this time to 333.3 ± 29.1 s. Pre-treatment with 10 μM ZnSO₄ did not potentiate platelet activation to CRP-XL (not shown).

Zinc induces tyrosine phosphorylation of platelet proteins

Tyrosine phosphorylation is a platelet actiavtory signalling event strongly induced by collagen and CRP-XL 17–19 and to a lesser extent induced by other platelet agonists. To provide further insight into the mechanisms responsible for zinc-induced aggregation, the extent of tyrosine phosphorylation in the platelet suspensions following treatment with zinc was examined. Exogenous zinc (1 mM) induced tyrosine phosphorylation in a time-dependent manner (Fig. 4A). Increased phosphorylation of high molecular weight proteins was visible after 30 s. Thrombin (0.1 U mL⁻¹) induced few tyrosine phosphorylation events, as previously reported 20 (Fig. 4B). Interestingly, ZnSO₄ treatment (0.1 mM) induced a pattern of tyrosine phosphorylation which differed from that observed in response to CRP-XL or thrombin. High MW proteins phosphorylated by ZnSO₄ treatment were absent following CRP-XL treatment, whilst a low MW protein (consistent in size with the FcγR 19) was phosphorylated by ZnSO₄ treatment.
CRP-XL but not ZnSO₄. Additionally, pre-treatment of platelets with 50 mM TPEN resulted in increased tyrosine phosphorylation of a high molecular weight protein (approximately 95 kDa). TPEN reduced phosphorylation of platelet proteins following stimulation with 0.1 mM ZnSO₄ and 0.1 μM L/CO₁ thrombin, but had little effect on phosphorylation initiated by 1 mM CRP-XL.

Zinc-induced aggregation is independent of GpVI-mediated activation

The mechanism by which zinc causes platelet aggregation is unclear. As PKC and Ca²⁺ signalling are downstream of GpVI engagement, we examined the involvement of GpVI in zinc-induced activation. Pre-treatment of platelet suspensions with the GpVI-blocking antibody, 1C3, resulted in a reduced response to CRP-XL, whilst zinc-induced aggregation was unaffected (Fig. 5A). 1C3 reduced aggregation induced by 0.1 mM CRP-XL to 9.5 ± 5.6% whilst 300 μM ZnSO₄ treatment resulted in 104.7 ± 8.0% aggregation (Fig. 5A and B). Thus, GpVI-functionality is not a prerequisite for zinc-induced aggregation.

The influence of zinc on platelet adhesive receptor activity was further investigated by examining receptor-specific platelet adhesion using collagen-mimetic peptides. GR144053-treated platelet suspensions treated with 100 μM ZnSO₄ displayed a significant increase in binding activity to GpVI-binding peptides (CRP, III-1 and III-30), whilst binding to α₂β₁-binding peptides (GFQGER, GLOGEN and II-28) was not affected (Fig. 5C). For adhesion to GpVI-adhesive peptides, A₄₀₅ values were 0.8 ± 0.1 and 1.4 ± 0.2 for untreated and 100 μM zinc treated platelets respectively on CRP, and 0.5 ± 0.1 and 1.0 ± 0.2 on III-30. On GFOGER, absorbance values were 1.1 ± 0.3 and 1.2 ± 0.4 respectively. These data indicate a selective role for zinc in increasing the affinity of GpVI for its cognate ligand.

Exogenous zinc gains access to the platelet cytosol

Zinc-induced platelet activation may occur as a result of zinc entry into the platelet cytosol. To investigate this possibility we loaded platelets with the zinc-sensitive indicator Fluorozin-3 and assessed changes of fluorescence in response to exogenously applied ZnSO₄. Using fluorometry, concentration dependent increases of fluorescence were observed following stimulation of platelet suspensions by extracellular zinc (Fig. 6A). To further assess the localisation of Fluorozin-3 fluorescence confocal microscopy was employed. Fluorozin-3-loaded platelets were adhered to collagen-coated coverslips and changes of intracellular fluorescence were imaged in response to exogenous zinc. Treatment with 10 μM ZnSO₄ following platelet adhesion resulted in observable increases of intracellular fluorescence over time (Fig. 6B). This is consistent with increases in...
This journal is © The Royal Society of Chemistry 2016 Metallomics, 2016, 8, 91-100 | 95

Cytosolic zinc, demonstrating that exogenous zinc gains access to the platelet cytosol.

**TPEN inhibits platelet activation induced by multiple agonists**

To investigate the role of zinc in intracellular signalling processes, we examined aggregation of TPEN-treated platelets. Platelet aggregation induced by CRP-XL, U46619 or ZnSO₄ was fully abrogated in TPEN-treated platelets, whilst aggregation induced by thrombin or A23187 was inhibited at low agonist concentrations (Fig. 7A-E).

We used a whole-blood perfusion system with collagen or collagen-mimetic peptides as substrates to examine receptor-specific platelet adhesion and activation under physiologically relevant flow conditions (Fig. 7F-I).

Surface coverage was relatively unaffected by TPEN treatment, with an increase only being seen on a VWF-III/CRP surface (from 22.7 ± 3.8% to 45.3 ± 10.8%, Fig. 7G).

The end-point parameter ZV₅₀ reports platelet–platelet interactions, quantifying platelet activation under flow conditions (Fig. 7H).²¹ On CRP/GFGER, 50 μM TPEN reduced ZV₅₀ from 3.6 ± 0.3 μm to 1.2 ± 0.2 μm, whilst on CRP/GFGER/VWF-III, ZV₅₀ was reduced from 3.2 ± 0.3 μm to 1.4 ± 0.2 μm. On VWF-III/CRP, ZV₅₀ was reduced from 3.5 ± 1.3 μm to 1.3 ± 0.1 μm. TPEN treatment did not affect ZV₅₀ on any other surfaces. We used “platelet mobility” (PM) as a real time parameter to quantify the effect of TPEN on stable platelet adhesion.²² On all surfaces tested, PM was unaffected by TPEN treatment (Fig. 7I). Thus, TPEN reduces platelet thrombus formation, without affecting the ability of platelets to achieve stable adhesion.
Conclusions

The role of zinc in platelet activation and pathophysiological thrombus formation has received little attention, despite having been shown to be an important and physiologically relevant cofactor in haemostasis.\textsuperscript{5,10,11,13,15,16} Zinc as a signalling factor has been overlooked in favour of Ca\textsuperscript{2+}, which is considered the more important cation for platelet function owing to its higher concentration and more readily observable fluctuations during platelet activation.\textsuperscript{23} Whilst the work presented here does not challenge this view, it should be noted that commonly used Ca\textsuperscript{2+} chelating agents and fluorophores have higher affinities for zinc (for example, the $K_d$s of BAPTA for calcium and zinc are 160 nM and 0.5 nM respectively, whilst Fura-2 has $K_d$s of 145 nM and 3 nM). Use of such reagents may have resulted in an underestimation of the role and significance of zinc in platelet activation.

Here we show that exogenous zinc gains access to the platelet cytosol and is able to activate platelets. Chelation of intracellular zinc results in a reduction of platelet aggregation, tyrosine phosphorylation and thrombus formation under flow conditions. These data support a transmembrane signalling role for zinc in platelet activation.

We confirm previous observations that zinc is a potent platelet agonist at millimolar concentrations, and can potentiate platelet aggregation by other agonists at lower concentrations. Free zinc is present in blood at a concentration of 0.5–1 $\mu$M rising to 6–10 $\mu$M in the close proximity of platelet membranes.\textsuperscript{5} However, zinc is released from activated platelets and damaged cells\textsuperscript{6–9} so is likely to be concentrated at sites of vascular injury. It is not unreasonable to suggest that higher local concentrations of zinc may be achieved in a growing thrombus, indicating that the potentiating effect observed here and by others\textsuperscript{2,15} may be pathophysiologically relevant.

**Fig. 6** Exogenous zinc gains access to the platelet cytosol. (A) Fluorometric imaging of Fluozin-3-stained platelet suspensions following addition of increasing concentrations of ZnSO\textsubscript{4}. (B) Collagen-adhered Fluozin-3-loaded platelets were perfused with 10 $\mu$M ZnSO\textsubscript{4} and imaged by confocal microscopy. This representative time-lapse image sequence shows increases in cytosolic zinc approximately 20 s after onset of perfusion.

**Fig. 7** TPEN inhibits platelet activation. Platelets were pre-treated with 50 $\mu$M TPEN (●) or vehicle (○) before being challenged with different concentrations of platelet agonists during aggregometry. (A) CRP-XL, (B) thrombin, (C) ZnCl\textsubscript{2}, (D) U46619, (E) A23187. In all cases a reduction in aggregation as a result of TPEN treatment was observed. Platelets in whole blood were treated with 50 $\mu$M TPEN before being perfused across fibrillar collagen, or combinations of collagen mimetic peptide as described in the text. (F) Representative images of platelet thrombi formed following pre-treatment with vehicle (left panel) or 50 $\mu$M TPEN (right panel). Quantitative assessment of images of thrombi forming on thrombogenic surfaces under flow conditions. (G) Thrombus or platelet surface coverage, (H) ZV\textsubscript{50} and (I) plateau, derived from platelet mobility (PM, see Methods).
Additionally, under conditions of extensive platelet activation, zinc concentrations may reach levels that could activate platelets directly, contributing to thrombus formation.

In our experiments, we have used concentrations of zinc up to and including millimolar levels. Whilst unlikely to represent the physiological situation, these levels have allowed us to probe the mechanisms by which platelets respond to zinc. This strategy has been employed by others in the investigation of platelet signalling pathways with different agonists. For example, the physiological concentration of collagen experienced by platelets during vascular injury is not known, but high concentrations of CRP-XL have been used to investigate GpVI function.\(^{19,24,25}\) To address the pathophysiological significance of zinc, we also used lower concentrations of zinc to investigate potentiation of platelet activation. Zinc-induced platelet aggregation is sensitive to inhibition of \(\alpha_{IIb}\beta_{3}\), demonstrating an activatory effect, rather than non-specific cation-induced agglutination. We provide evidence that zinc is not an extracellular stimulus, but gains access to the platelet cytosol to activate platelets. Zinc entry into platelets was observed with confocal microscopy and fluorometry using Fluozin-3 stained platelets. Other cations that have previously been shown to activate integrins (such as \(\text{Mn}^{2+}\))\(^{26}\) had no effect on platelet aggregation.

The mechanism by which zinc gains access to the platelet cytosol is not known. Zinc, and other divalent cation channels and transporters are present in the platelet proteome, but have yet to be investigated in the context of zinc induced activation. Assessment of the roles of specific channels or transporters in zinc entry must await future studies utilising specific blocking agents. Identification of such blocking reagents would assist in the evaluation of the physiological relevance of zinc in platelet behaviour. It is important to note that our experiments have been carefully designed to preclude contributions by exogenous \(\text{Ca}^{2+}\) (i.e. nominally \(\text{Ca}^{2+}\)-free salines). Whilst these conditions are somewhat removed from the physiological situation, we observe normal platelet aggregation responses to the major agonists CRP-XL, thrombin and U46619 (Fig. 2 and 7). However, we cannot exclude the possibility that zinc-induced aggregation coincides with the release of intracellular \(\text{Ca}^{2+}\) and activation of store operated \(\text{Ca}^{2+}\) entry. Extracellular \(\text{Ca}^{2+}\) has previously been shown to be required for platelet responses to phorbol-myristate acetate (PMA) in zinc deficient rats.\(^{27}\) It is intriguing to postulate that zinc and calcium may have a synergistic relationship. This remains an important area of study and will be the focus of future research.

Zinc-induced activation resulted in tyrosine phosphorylation of platelet proteins, granule release and secondary activation leading to \(\alpha_{IIb}\beta_{3}\) activation, whilst zinc chelation inhibited phosphorylation and aggregation in response to multiple agonists. This indicates a correlation between zinc-induced phosphorylation and aggregation.

Similarities were observed between GpVI- and zinc-induced platelet activation. Both involve substantial protein tyrosine phosphorylation, and both are less dependent on secondary signalling than thrombin-induced aggregation. However, the pattern of protein phosphorylation induced by the two agonists is sufficiently different to suggest an alternative mechanism. The absence of clear \(\text{Fc}\gamma\text{R}\) phosphorylation following zinc treatment suggests that zinc acts downstream of GpVI dimerization and Src-dependent \(\text{Fc}\gamma\text{R}\) phosphorylation. However, this is not consistent with the observation that zinc causes upregulation of GpVI-dependent platelet adhesion. The nature of the increased adhesive response of GpVI is not known, but may involve promotion of receptor dimerization.\(^{23}\) This may be regulated by increases in cytosolic zinc concentrations or by a direct extracellular effect on GpVI. Our results are suggestive of an inside-out and outside-in scheme of GpVI regulation that is reminiscent of integrin behaviour in platelets and other cells. This is a novel and interesting possibility that warrants further research.

Involvement of PKC in zinc-induced aggregation is inferred from inhibition of aggregation by PKC inhibitors. Whether an increase in cytosolic calcium is required for zinc-induced activation is not known and would be difficult to assess empirically due to the higher affinity for zinc over calcium of conventional calcium indicators and chelators. However, zinc has also been shown to affect PKC activity in platelets and lymphocytes, by increasing association with the cell membrane.\(^{28}\) Additionally, the biphasic aggregometry response to zinc indicates a role for granule release in full activation, further implicating PKC in zinc-induced aggregation.\(^{29}\) This is further supported by the observation that combined inhibition of P2Y12, P2X1 and thromboxane signalling results in partial aggregation following zinc treatment (an inhibition-resistant activation profile) demonstrating elements of an activatory response that are independent of granule release. Again, this resembles GpVI-rather than thrombin-induced aggregation and may reflect partial increase of \(\alpha_{IIb}\beta_{3}\) activity in the absence of secondary signalling.

The phosphorylation of high molecular weight proteins indicates that kinase or phosphatase activity is affected by exogenous zinc. The pattern of phosphorylation differed from that of GpVI- and protease activated receptor (PAR) dependent phosphorylation, suggesting the involvement of different kinases and substrates. Interestingly, chelation of intracellular zinc with TPEN resulted in the phosphorylation of a 95 kDa protein, indicating the activity of kinases or phosphatases that are sensitive to intracellular zinc levels. TPEN treatment inhibited zinc- and PAR-dependent protein tyrosine phosphorylation but had little effect on GpVI-mediated phosphorylation. This may indicate conservation of PAR and zinc-dependent signalling mechanisms.

Zinc is released from platelets and is likely to affect platelets within a growing thrombus.\(^{7}\) However, the extent of the influence of zinc on pathophysiological thrombus formation is not known.

This journal is © The Royal Society of Chemistry 2016
Here, we demonstrate that chelation of intracellular zinc inhibits thrombus formation under physiologically relevant flow conditions. This work does not directly investigate signalling, but highlights a role for zinc in platelet activation. Given the number and variety of zinc-binding proteins in the platelet cytosol, an effect on activation is not surprising.

Potentiation of platelet aggregation with sub-activatory levels of zinc may provide evidence for a physiological role of zinc in platelet activation. Potentiation increased the efficacy of low concentrations of platelet agonists that act via GpVI and PARs. Interestingly, potentiation of adrenaline-induced activation led to a reduction in the time taken to achieve aggregation, but not in the final extent of aggregation. We propose that zinc released from activated platelets or damaged cells will potentiate the activation of other platelets in a growing thrombus. This hypothesis will be testable following the identification of specific antagonists that block zinc entry into platelets.

In conclusion, our data confirm previous observations of a role for zinc as a platelet agonist. We provide data demonstrating a potentiating role for sub-activatory levels of zinc during platelet activation by other agonists. Zinc enters the platelet cytosol and regulates protein phosphorylation-dependent platelet signalling events, leading to granule release and full PKC-mediated αβ3-dependent aggregation. Although similarities exist between zinc-activation and GpVI or PAR-mediated activation, sufficient differences remain to suggest a novel mechanism. Furthermore, chelation of platelet zinc inhibits platelet activation and tyrosine phosphorylation, indicating a role for intracellular zinc in platelet function. Whilst this work does not address the physiological relevance of zinc in thrombus formation, we speculate that zinc is acting as a transmembrane signalling ion.

**Experimental**

**Ethical approval**

Whole blood was obtained from healthy volunteers, free from medication for two weeks, after consent in accordance with the Declaration of Helsinki and our Institutional guidelines, as approved by the local ethics committee.

**Materials**

NF449 (4,4′,4″-[carboxyl bis(iminoo-5,1,3-benzene)trikis-1,3-benzenedisulfonic acid, octasodium salt], 2-MeSAMP [methylthioadenosine 5′-monophosphate triethylammonium salt hydrate) and GPO19203XX [2-[[3-[dimethylamino]propyl]indol-3-yl]-3-indol-3-yl]maleimide] were from Toeris, UK. Fluozin-3-AM was from Invitrogen, UK. GR144053 (4-4′-[aminominomethyl]phenyl-1-piperazinyl]-1-piperidineacetic acid trihydrochloride hydrate) was from Novabiochem, UK. PPACK (Phe-Pro-Arg-chloromethylketone) was from Cambridge Bioscience, UK. Bovine tendon collagen I fibres were the gift of Ethicon Corp (New Jersey, USA). The anti-GpVI ScFv 1C3 has previously been described.29 TPEN (N,N,N′,N″-tetrakis(2-pyridylmethyl) ethylenediamine), aspirin, progtaglandin E1 (PGE1), DiOC6 (3,3′-dihexyloxacarbocyanine iodide), DM-BAPTA-AM (dimethyl-1,2-bis(o-aminophenoxy)ethane-N,N′,N″,N‴-tetraacetic acid) and other chemicals were from Sigma-Aldrich, UK. Cross-linked CRP (CRP-XL) was prepared as previously described.27 Collagen-mimetic peptides were prepared as previously described,24,31–33 Peptides used in these experiments included:

- CRP: GCO(GP)OOGC-amide (where O indicates hydroxyproline);
- GFOGER: GPC(GP)OOGFGER(GP)OOGC-amide;
- VWF-III: GPC(GP)OOGPRGQOGVMGO(GP)OOGC-amide;
- GLOGEN: GPC(GP)OOGLOGEN(GP)OOGC-amide;
- GPP10: GPC(GP)OOGC-amide;
- III-1: GPC(GP)OOGAGYOGAGOOGPOGAGPOGTSAGHOGSO(GP)OOGC-amide;
- III-12: GPC(GP)OOGQGRQOGHAGAOOGPIOGINO(GP)OOGC-amide;
- III-30: GPC(GP)OOGQGRQOGHAGAOOGPIOGINO(GP)OOGC-amide;
- III-33: GPC(GP)OOGQGRQOGHAGAOOGPIOGINO(GP)OOGC-amide;

**Platelet preparation**

Whole blood was collected into 11 mM sodium citrate and centrifuged to obtain PRP (240 g, 15 min). 2 μM prostaglandin E1 (PGF1α, Sigma-Aldrich) was added and the PRP centrifuged (640 g, 15 min). The pellet was resuspended to 2 × 10^8 platelets per mL in calcium-free Tyrodes buffer (CFT, 10 mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid (HEPES), 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 5 mM glucose, 0.42 mM Na2HPO4, 12 mM NaHCO3, pH 7.4). Platelet suspensions were rested for 30 min at 37 °C before use.

**Aggregometry**

Aggregation experiments were performed at 37 °C in an AggRam aggregometer (Helena Biosciences, UK). Briefly, 250 μL of platelet suspension was aliquoted into a cuvette along with a magnetic stir bar. 100% aggregation was calibrated using CFT. Agonists or antagonists were added (1% v/v) and aggregation was recorded with stirring (1000 rpm) for 15 min. Maximal aggregation and the time to 50% aggregation were calculated. Platelet suspensions were treated with inhibitors, potentiating concentrations of ZnSO4 (indicated in the text) or vehicle control for 15 min prior to each experiment.

**Western blotting**

Western blotting was performed as described previously.34 Briefly, washed platelet suspensions (2 × 10^9 mL^-1) were stimulated under stirring conditions in the presence of reagents stated in the text. At given time points, platelets were lysed and boiled for 5 minutes. Samples were resolved by 10% SDS-PAGE and transferrered onto a nitrocellulose membrane. Membranes were reprobed with an anti-phosphotyrosine primary antibody (4G10; Fisher, UK) and anti-mouse HRP-conjugated secondary antibodies. Equal amounts of proteins were loaded onto each lane, and was assessed by coomassie blue staining of the nitrocellulose membrane. Data are representative of a minimum of three independent experiments using platelets from different donors; representative blots are shown.

**Intracellular zinc measurements of Fluozin-3-stained platelets**

For fluorometry, PRP was incubated with 2 μM Fluozin-3-AM (Invitrogen) for 45 min at 37 °C. Platelets were collected by
centrifugation (350 g, 20 min) and resuspended in CFT to 8 × 10^6 mL⁻¹. Fluorescence was recorded from 1.5 mL stirred aliquots of platelet suspension at 37 °C using a Cairn Research Spectrophotometer (Cairn Research, UK) with excitation at 488 nm and emission at 516 nm. For confocal microscopy, Fluozin-3-stained platelets were adhered to type I collagen fibres on a coverslip for 15 min. Following washing, adhered platelets were perfused with 10 μM ZnSO₄, during which images were acquired using FV300 laser-scanning confocal microscope (Olympus, UK) with excitation at 488 nm and emission at 510–530 nm.

**Static adhesion assay**

The adhesion of platelets to collagen or collagen mimetic peptides adsorbed to microtitre plates under static conditions at 21 °C after 60 min was measured using a colorimetric assay as previously described. The peptides used included ligands for GpVI (CRP, III-1, III-30, type I collagen), integrin α₂β₁ (II-28, GLOGEN, type I collagen), and inert peptides (GPP₁₀, III-12 and III-33). The adhesion of platelets to collagen or collagen mimetic peptides adsorbed to microtitre plates under static conditions at 21 °C after 60 min was measured using a colorimetric assay as previously described. The peptides used included ligands for GpVI (CRP, III-1, III-30, type I collagen), integrin α₂β₁ (II-28, GLOGEN, type I collagen), and inert peptides (GPP₁₀, III-12 and III-33). The adhesion of platelets to collagen or collagen mimetic peptides adsorbed to microtitre plates under static conditions at 21 °C after 60 min was measured using a colorimetric assay as previously described. The peptides used included ligands for GpVI (CRP, III-1, III-30, type I collagen), integrin α₂β₁ (II-28, GLOGEN, type I collagen), and inert peptides (GPP₁₀, III-12 and III-33).

**Confocal microscopy**

For perfusion studies, whole blood was taken into 40 μM PPACK, supplemented with 10 μM PPACK hourly. Platelets in whole blood were stained with 5 μM DIOC₆ for 15 min before use. Perfusion studies were performed as described with some modification. Briefly, glass coverslips were coated with collagen fibres or combinations of collagen-mimetic peptides. Each peptide, dissolved in 0.01 M acetic acid, was coated at 0.1 mg mL⁻¹ in a mixture containing a total of 0.3 mg mL⁻¹ of peptide. For surfaces where only 1 or 2 active peptides were applied, the total peptide concentration was made up to 0.3 mg mL⁻¹ with the inert homolog GPP₁₀. Collagen was coated at 0.1 mg mL⁻¹. Coverslips were covered with peptide solution and held in a humid chamber overnight at 4 °C. After removal of excess fluid, they were blocked with 1% bovine serum albumin in HEPES buffer (36 mM NaCl, 2.7 mM KCl, 5 mM HEPES, 10 mM glucose, 2 mM MgCl₂, 2 mM CaCl₂). The coverslip, in a 125 μm deep flow chamber, was mounted on an FV300 laser-scanning confocal microscope (Olympus, UK) and washed for 1 min with HEPES buffer. Blood was drawn through the chamber for 5 min using a syringe pump at a calculated wall shear rate of 1000 s⁻¹ after which residual blood was flushed with HEPES buffer before image acquisition. Where stated, whole blood was pre-incubated with TPEN for 15 min at 37 °C. Images were acquired at 0.2 Hz (for morphology experiments) and subjected to image analysis to generate parameters of thrombus formation including surface coverage and ZV₃₀, ZV₅₀ quantifies the height of a field of thrombi at which the thrombus volume is half maximal. This value correlates with platelet activation. Additional dynamic parameters of platelet mobility were calculated as previously described. The parameter reported here (plateau) reports the relationship between the extent of stable adhesion achieved by a platelet population and perfusion time.

**Data analysis**

Values are expressed as the mean ± standard error of the mean. Experiments were repeated on at least four occasions using blood from different donors. Differences among mean values were identified using analysis of variance, and post hoc comparisons used Student–Newman–Keuls or Student t tests with residual degrees of freedom and residual mean square to calculate pooled SD.

**Abbreviations**

PKC Protein kinase C  
CRP-XL Cross linked collagen-related peptide  
ADP Adenosine diphosphate  
ATP Adenosine triphosphate  
PRP Platelet rich plasma  
PPACK Phe-Pro-Arg-chloromethylketone  
PGE₁ Prostaglandin E₁  
CFT Calcium free Tyrodes buffer  
α₃β₃ Integrin α₃β₃  

**Acknowledgements**

This work was funded by British Heart Foundation grants to NP (Project PG/14/47/30912), to RWF (Programme RG/09/003/27122), New Horizons (NH/11/1/28922), and Wellcome Trust support to RWF (094470/Z/10/Z).

**References**

9. H. Sharir, A. Zinger, A. Nevo, I. Sekler and M. Hershfinkel, Zinc released from injured cells is acting via the


31 C. G. Knight, et al., The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens, *J. Biol. Chem.*, 2000, **275**, 35–40.


